SOUTH KOREA · OPENDART
Onconic Therapeutics Inc.
온코닉테라퓨틱스 · 476060 · KOSDAQ · Healthcare · Drug Manufacturers—Specialty & Generic
Score
Not ranked: no net buying on the exchange by an individual insider in the last 180 days.
Insider timeline
No purchase in the last 180 days; 2 insiders sold.
Tap an item for what it means.
×A sale
A cross is one insider's sales on one day. People sell to pay tax, to cash in share awards or to hold less of one company, so a sale says less than a purchase does. When someone bought and sold on the same day, the cross sits beside the dot. The totals are under “Purchases against sales” below.
Blue line: this share's price, −38.4% over these six months
The closing price of each day, from 22,550.00 on 2026-04-21 to 13,900.00 on 2026-10-16. The line has no scale; read it for high and low: a dot on a low stretch was bought cheaply, a dot on a high stretch was not.
Dashed line: the typical stock on the same exchange, −31.9%
Taken from the 1525 other stocks on the same exchange that this site holds prices for. Each is measured from the first day of the window, and every day the middle one is drawn. It starts where the blue line starts, so the gap between the two is the difference: this share −38.4%, the typical one −31.9%, 6.5 points behind. It is not an index and not a comparison within one industry.
This company: insiders buying per month, last 12 months
Darker bars are inside the 180-day window above.
Who traded
| Insider | Role | Purchases | Sales | Bought | First purchase | Share price since |
|---|---|---|---|---|---|---|
| Cha Hyeon-ju | Executive | — | 1 | — | — | — |
| John Kim | CEO / chair | — | 5 | — | — | — |
Insiders' buying price vs the latest close
Insiders paid 18,820.35 KRW a share on average (4 purchase lines, 1 buyer, 2026-01-13 – 2026-02-20). The close on 2026-10-16 was 26.1% below that price.
The latest purchase (2026-02-20) was at 19,078.00 KRW; the close was 27.1% below that price.
Prices paid are weighted by shares and taken from the filings; dividends are not counted. Not scored.
Insider trades on the exchange
Purchases and sales on the exchange in the last 12 months. The filing gives the settlement date; the trade date is two trading days earlier.
| Trade date | Insider | Role | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | John Kim | CEO | Sold on the exchange | 19,962 | ₩13,600 | ₩271.5M | DART ↗ |
| 2026-06-29 | John Kim | CEO | Sold on the exchange | 87,743 | ₩13,669 | ₩1.2B | DART ↗ |
| 2026-06-25 | John Kim | CEO | Sold on the exchange | 12,300 | ₩14,973 | ₩184.2M | DART ↗ |
| 2026-06-24 | John Kim | CEO | Sold on the exchange | 80,987 | ₩14,313 | ₩1.2B | DART ↗ |
| 2026-06-02 | John Kim | CEO | Sold on the exchange | 28,577 | ₩17,558 | ₩501.8M | DART ↗ |
| 2026-04-24 | Cha Hyeon-ju | Managing director | Sold on the exchange | 20,000 | ₩22,208 | ₩444.2M | DART ↗ |
| 2026-04-01 | Kim Jin-seong | Managing director | Sold on the exchange | 33,000 | ₩22,253 | ₩734.3M | DART ↗ |
| 2026-02-20 | SHIN JONGKIL | Senior managing director | Bought on the exchange | 11,032 | ₩19,078 | ₩210.5M | DART ↗ |
| 2026-02-19 | SHIN JONGKIL | Senior managing director | Bought on the exchange | 15,802 | ₩18,295 | ₩289.1M | DART ↗ |
| 2026-02-13 | SHIN JONGKIL | Senior managing director | Bought on the exchange | 27,184 | ₩18,379 | ₩499.6M | DART ↗ |
| 2026-01-13 | SHIN JONGKIL | Senior managing director | Bought on the exchange | 13,373 | ₩20,126 | ₩269.1M | DART ↗ |
| 2025-12-26 | SHIN JONGKIL | Senior managing director | Sold on the exchange | 218,026 | ₩20,132 | ₩4.4B | DART ↗ |
| 2025-12-26 | SHIN JONGKIL | Senior managing director | Sold on the exchange | 12,528 | ₩21,551 | ₩270.0M | DART ↗ |
| 2025-12-26 | SHIN JONGKIL | Senior managing director | Sold on the exchange | 218,026 | ₩20,132 | ₩4.4B | DART ↗ |
| 2025-12-26 | SHIN JONGKIL | Senior managing director | Sold on the exchange | 12,528 | ₩21,551 | ₩270.0M | DART ↗ |
| 2025-12-26 | John Kim | CEO | Sold on the exchange | 120,000 | ₩20,345 | ₩2.4B | DART ↗ |
| 2025-12-24 | John Kim | CEO | Sold on the exchange | 40,000 | ₩18,907 | ₩756.3M | DART ↗ |
Other changes in holdings · 41
Option exercises, grants, new shares, inheritance, gifts, off-exchange trades and trades by companies and funds. Not counted in the score.
| Date | Insider | Role | Reason | Shares | Filing |
|---|---|---|---|---|---|
| 2026-04-13 | Han Sang-cheol | President | New appointment(+) | 22,847 | DART ↗ |
| 2026-04-10 | John Kim | CEO | Exercise of appraisal rights(+) | 140,000 | DART ↗ |
| 2026-04-10 | Cha Hyeon-ju | Managing director | Exercise of appraisal rights(+) | 90,000 | DART ↗ |
| 2026-04-10 | SHIN JONGKIL | Senior managing director | Exercise of appraisal rights(+) | 130,000 | DART ↗ |
| 2026-04-10 | Kim Jin-seong | Managing director | Exercise of appraisal rights(+) | 72,000 | DART ↗ |
| 2026-01-02 | SHIN JONGKIL | Senior managing director | Exercise of appraisal rights(+) | 131,974 | DART ↗ |
| 2026-01-02 | SHIN JONGKIL | Senior managing director | Exercise of appraisal rights(+) | 131,974 | DART ↗ |
| 2026-01-02 | John Kim | CEO | Exercise of appraisal rights(+) | 260,000 | DART ↗ |
| 2025-11-04 | John Kim | CEO | Exercise of appraisal rights(+) | 30,000 | DART ↗ |
| 2025-11-03 | Jeil Pharmaceutical Co.,L | 10% shareholder | Acquisition of new shares without compensation(+) | 15,754,284 | DART ↗ |
| 2025-10-28 | Cha Hyeon-ju | Managing director | Exercise of appraisal rights(+) | 5,200 | DART ↗ |
| 2025-10-28 | SHIN JONGKIL | Senior managing director | Exercise of appraisal rights(+) | 7,626 | DART ↗ |
| 2025-10-28 | Cha Hyeon-ju | Managing director | Exercise of appraisal rights(+) | 5,200 | DART ↗ |
| 2025-10-28 | SHIN JONGKIL | Senior managing director | Exercise of appraisal rights(+) | 7,626 | DART ↗ |
| 2025-10-28 | John Kim | CEO | Exercise of appraisal rights(+) | 40,000 | DART ↗ |
| 2025-10-13 | Cha Hyeon-ju | Managing director | Acquisition of new shares without compensation(+) | 108,600 | DART ↗ |
| 2025-10-13 | SHIN JONGKIL | Senior managing director | Acquisition of new shares without compensation(+) | 167,196 | DART ↗ |
| 2025-10-13 | Jeil Pharmaceutical Co.,L | 10% shareholder | Acquisition of new shares without compensation(+) | 15,000,000 | DART ↗ |
| 2025-10-13 | SHIN JONGKIL | Senior managing director | Acquisition of new shares without compensation(+) | 292,908 | DART ↗ |
| 2025-10-13 | Cha Hyeon-ju | Managing director | Acquisition of new shares without compensation(+) | 128,712 | DART ↗ |
| 2025-10-13 | John Kim | CEO | Acquisition of new shares without compensation(+) | 210,000 | DART ↗ |
| 2025-10-13 | Kim Jin-seong | Managing director | Acquisition of new shares without compensation(+) | 36,000 | DART ↗ |
| 2025-09-16 | Cha Hyeon-ju | Managing director | Exercise of appraisal rights(+) | 8,700 | DART ↗ |
| 2025-09-16 | SHIN JONGKIL | Senior managing director | Exercise of appraisal rights(+) | 4,500 | DART ↗ |
| 2025-09-16 | John Kim | CEO | Exercise of appraisal rights(+) | 20,000 | DART ↗ |
| 2025-09-16 | Cha Hyeon-ju | Managing director | Exercise of appraisal rights(+) | 8,700 | DART ↗ |
| 2025-09-16 | SHIN JONGKIL | Senior managing director | Exercise of appraisal rights(+) | 4,500 | DART ↗ |
| 2025-09-16 | Kim Jin-seong | Managing director | Exercise of appraisal rights(+) | 12,000 | DART ↗ |
| 2025-04-15 | Cha Hyeon-ju | Managing director | Exercise of appraisal rights(+) | 12,500 | DART ↗ |
| 2025-04-15 | SHIN JONGKIL | Senior managing director | Exercise of appraisal rights(+) | 18,100 | DART ↗ |
| 2025-04-15 | John Kim | CEO | Stock options(+) | 50,000 | DART ↗ |
| 2025-04-15 | Cha Hyeon-ju | Managing director | Exercise of appraisal rights(+) | 12,500 | DART ↗ |
| 2025-04-15 | SHIN JONGKIL | Senior managing director | Exercise of appraisal rights(+) | 18,100 | DART ↗ |
| 2025-03-14 | Cha Hyeon-ju | Managing director | Exercise of appraisal rights(+) | 15,000 | DART ↗ |
| 2025-03-14 | SHIN JONGKIL | Senior managing director | Exercise of appraisal rights(+) | 30,000 | DART ↗ |
| 2025-03-14 | Cha Hyeon-ju | Managing director | Exercise of appraisal rights(+) | 15,000 | DART ↗ |
| 2025-03-14 | SHIN JONGKIL | Senior managing director | Exercise of appraisal rights(+) | 30,000 | DART ↗ |
| 2024-12-19 | Jeil Pharmaceutical Co.,L | 10% shareholder | New listing(+) | 5,000,000 | DART ↗ |
| 2024-12-19 | Cha Hyeon-ju | Managing director | 신규상장(+) | 6,704 | DART ↗ |
| 2024-12-19 | Jeil Pharmaceutical Co.,L | 10% shareholder | 신규상장(+) | 5,251,428 | DART ↗ |
| 2024-12-19 | SHIN JONGKIL | Senior managing director | 신규상장(+) | 41,904 | DART ↗ |